

**The International Bladder Cancer Network**  
***September 20<sup>th</sup> - 22<sup>nd</sup>, 2012 in Nijmegen/The Netherlands,***


Dear friends and colleagues,

With the attached agenda we tried to implement all possible current approaches to foster our understanding of bladder cancer. The rich interdisciplinary diversity clearly mirrors the expertise the attendees and we really are delighted to be able to provide such a promising program.

Again the IBCN would like to acknowledge the support through this year's meeting presidents, **Fred Witjes** and **Bart Kiemeneij**, who helped to organize the meeting in Nijmegen and who have agreed to provide their service to the group.

In addition, our special thanks are extended to **Simone van Wezel – Kloppenburg** and **Melissa Zenil** for their continuous support throughout the preparation of the meeting.

**Program 10<sup>th</sup> Meeting of the IBCN,**  
*in Nijmegen, The Netherlands September 20<sup>th</sup> – 22<sup>nd</sup>, 2012*



**Friday, 21<sup>st</sup> September 2012**

Time	Topic	
08:30 – 08:40	Welcome note The Netherlands/Nijmegen	Witjes/Kiemeneij
08:40 – 08:50	Welcome to the IBCN meeting	Schmitz-Dräger
08:50 – 09:00	Introduction and Administrative Notes	

**Key note lecture**

09:00 – 09:30	“Personalized medicine – hype or hope?”	Grossman
---------------	---	----------

**I. Project updates**

Chaired by: **Kamat, Schmitz-Dräger**

09:30 – 10:00	The International TMA SPORE project	Dinney
10:00 – 10:15	Using Markers in Monitoring NMIBC	Kamat
10:15 – 10:30	The T1G3 sub-staging project	van Rhijn

**Coffee break**

**II. Work in progress - Future needs**


Chaired by: **Kiemeneij, Knowles**

10:50 – 11:00	News on susceptibility in bladder cancer?	Zeegers
11:00 – 11:10	Title pending	Steineck
11:10 – 11:20	Chromosomal instability and bladder cancer - the UroScreen study	Pesch
11:20 – 11:30	Urine epigenomics – a promising path	Sanchez-Carbayo
11:30 – 11:40	Validating markers in the urine	Vlahou
11:40 – 11:50	Selective Urine analyses of the upper urinary tract	Todenhöfer
11:50 – 12:00	NucBio - Nordic Urothelial Cancer Group Trials in Tissue Microarrays	Segersten
12:00 – 12:10	Whole genome expression signatures - predictors of survival.	Black
12:10 – 12:20	CTCs or DTCs in Bladder Cancer ?	Nawroth
12:20 – 12:40	Cancer Genome: Lessons from Bladder Cancer	Czerniak
12:40 – 12:50	Differences in DNA methylation patterns of primary bladder tumors	Junker

**III. Strategies in low risk disease**

Chaired by: **Jankevicius, Grossman**

12:50 – 13:00	Re-TUR a clinical and economic challenge	Palou Redorta
13:00 – 13:10	The UROfollow trial – an update	Schmitz-Dräger



<b>IV. Chemotherapy – anything to improve?</b>		
Chaired by: <b>Sylvester, Witjes</b>		
13:10 – 13:20	Chemotherapy – the lesson(s) after 30 years	Goebell
13:20 – 13:40	Neoadjuvant treatment – the urologist perspective	Dinney
13:40 – 14:00	Neoadjuvant treatment – the oncologist perspective	Stadler

**Lunch break**


<b>V. Working group challenges</b>		
Chaired by: <b>Kiemeneij, Nawroth</b>		
15:00 – 15:15	Clinical challenges – clinical markers	Schmitz-Dräger
15:15 – 15:30	Next generation therapy for invasive disease	Dinney/Nawroth
15:30 – 15:45	Epidemiologic challenges	Kiemeneij/Witjes
15:45 – 16:00	Statistical needs	Sylvester

<b>VI. Working Groups 16:00 – 17:30</b>	<b>Room</b>
I. Diagnostic / molecular determinants	to be announced
II. Chemotherapy – next generation of Trials	to be announced
III. Epidemiology - Environment and Bladder Cancer	to be announced
IV. <b>Phases Reporting and Assessment Optimization (PHARAO)</b>	to be announced

<b>VII. IBCN e.V. – GA</b>
Chaired by: <b>Schmitz-Dräger</b>
Formal Structure IBCN e.V.
Discharge from liability
Elections

19:30	Reconvene for Dinner
	Place to be confirmed

**Program 10<sup>th</sup> Meeting of the IBCN,  
in Nijmegen, The Netherlands September 20<sup>th</sup> – 22<sup>nd</sup>, 2012**



**Saturday, 22<sup>nd</sup> September 2012**

**08:45 – 09:00 Summary – organizational needs**

**09:00 – 10:30 Working Group Sessions**

**Room**

I.	Diagnostic / molecular determinants	to be announced
II.	Chemotherapy – next generation of trials ??	to be announced
III.	Epidemiology - Environment and Bladder Cancer	to be announced
IV.	Phases Reporting and Assessment Optimization (PHARAO)	to be announced

**Report from Working Groups including plenary discussion**

10:30 - 11:00	I. Diagnostic / molecular determinants
11:00 - 11:30	II. Chemotherapy – next generation of trials ??
11:30 - 12:00	III. Epidemiology - Environment and Bladder Cancer
12:00 – 12:30	IV. Phases Reporting and Assessment Optimization (PHARAO)

**IV. Possible role for IBCN**

Chaired by: **Kamat, Schmitz-Dräger**

12:30 – 12:45	Network value and visibility	Droller
12:45 – 13:30	Next steps – Organizational needs homework – tasks – projects – papers	Chairs

**Lunch break - adjourn**